Abstract
The purpose of this study was to determine, using fluorescence in situ hybridization (FISH), whether treatment of cancer cells with 3'-azido-2'-3'-dideoxythymidine (AZT) has any effect on telomere length as determined by the telomeric signal intensity. To do so, we treated a metastatic murine melanoma cell line (K-1735 clone X-21) and a human breast cancer cell line (MCF-7) with three concentrations of AZT for 72 h at 37ûC. FISH preparations processed using an all-human telomeric DNA probe showed a significantly reduced, concentration-dependent telomeric signal intensity in interphase and metaphase spreads of AZT-treated cells as compared with the signal intensity in untreated controls, which showed no reduction. We conclude from these preliminary results that AZT has the potential of targeting the telomeric ends of chromosomes in cancer cells and promoting cell death and could well be tested along with other chemotherapy drugs given to cancer patients for this purpose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
